Unique ID issued by UMIN | UMIN000009914 |
---|---|
Receipt number | R000011616 |
Scientific Title | A randomized phase II study of Cisplatin plus S-1 versus Cisplatin plus Pemetrexed, with thoracic radiotherapy for locally advanced non-squamous non-small cell lung cancer |
Date of disclosure of the study information | 2013/01/31 |
Last modified on | 2020/12/01 14:18:09 |
A randomized phase II study of Cisplatin plus S-1 versus Cisplatin plus Pemetrexed, with thoracic radiotherapy for locally advanced non-squamous non-small cell lung cancer
Randomized phase II study of CDDP+S-1+TRT vs. CDDP+PEM+TRT for locally advanced non-sq NSCLC.
A randomized phase II study of Cisplatin plus S-1 versus Cisplatin plus Pemetrexed, with thoracic radiotherapy for locally advanced non-squamous non-small cell lung cancer
Randomized phase II study of CDDP+S-1+TRT vs. CDDP+PEM+TRT for locally advanced non-sq NSCLC.
Japan |
Non-squmous non-small cell lung cancer
Pneumology |
Malignancy
NO
To evaluate safety and efficacy of CDDP+S-1P+TRT and CDDP+PEM+TRT in patients with locally advanced non-squamous non-small cell lung cancer
Safety,Efficacy
Exploratory
Phase II
2-year progression-free survival rate
Rate of treatment completion, rate of adverse events, response rate, overall survival
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
YES
YES
Institution is considered as adjustment factor in dynamic allocation.
YES
Central registration
2
Treatment
Medicine |
Combination chemotherapy of S-1 plus cisplatin and concurrent thoracic radiotherapy
Combination chemotherapy of pemetrexed plus cisplatin and concurrent thoracic radiotherapy
20 | years-old | <= |
74 | years-old | >= |
Male and Female
(1) Pathologically proven non-squamous non-small cell lung cancer
(2) Clinical stage IIIA or IIIB based on the UICC TNM classification 7th edition
(3) Unresectable
(4) Having indication of defenitive thoracic radiotherapy
(5) No prior chemotherapy or radiotherapy
(6) ECOG PS of 0 or 1
(7) PaO2 >= 70 Torr or SpO2 >= 93%
(8) Adequate organ function
(9) Expected the rest of life over 12 weeks
(10) Age of 20 to 70 years
(11) Written informed consent by patients
(1) active concomitant malignancy
(2) Infection, ileus, or gastrointestinal obstruction
(3) Uncontrolled peptic ulcer or diabetes
(4) Intestinal pneumonia or severe emphysema
(5) Severe drug allergy
(6) Concomitant use of other investigational drugs, warfarin, or flucytosine
(7) Positive of HBsAg
(8) Pregnancy or breast-feeding
100
1st name | |
Middle name | |
Last name | Yuichiro Ohe |
National Cancer Center Hospital
Department of Thoracic Oncology
5-1-1, Tsukiji, Chuo-ku, Tokyo, Japan
03-3542-2511
yohe@ncc.go.jp
1st name | |
Middle name | |
Last name | Seiji Niho |
National Cancer Center Hospital East
Department of Thoracic Oncology
6-5-1, Kashiwanoha, Kashiwa, Chiba, Japan
04-7133-1111
siniho@east.ncc.go.jp
National Cancer Center Hospital East
AMED
Japanese Governmental office
Japan
Cancer Institute Hospital, Japanese Foundation for Cancer Research; Shizuoka Cancer Center
NO
癌研究会有明病院、静岡県立静岡がんセンター、九州がんセンター、愛知県がんセンター中央病院、国立がん研究センター中央病院、関西医科大学附属枚方病院、横浜市立市民病院、兵庫県立がんセンター
2013 | Year | 01 | Month | 31 | Day |
Unpublished
Main results already published
2012 | Year | 12 | Month | 05 | Day |
2012 | Year | 11 | Month | 01 | Day |
2013 | Year | 01 | Month | 04 | Day |
2019 | Year | 01 | Month | 16 | Day |
2019 | Year | 02 | Month | 19 | Day |
2013 | Year | 01 | Month | 31 | Day |
2020 | Year | 12 | Month | 01 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011616